Exiqon launches two new Research Use Only kits for PCR analysis of colon cancer samples.
18 déc. 2014 09h51 HE
|
Exiqon A/S
Copenhagen, 2014-12-18 15:51 CET (GLOBE NEWSWIRE) --
Exiqon A/S today launched the miRSIGN™ miR-21 Oncogene assay, a Research Use Only kit for measuring miR-21 levels in relation to two...
Exiqon lancerer to nye ‘Research Use Only’ kits til PCR analyse af kræftceller i vævsprøver fra tyktarmen.
18 déc. 2014 09h51 HE
|
Exiqon A/S
København, 2014-12-18 15:51 CET (GLOBE NEWSWIRE) --
Exiqon A/S offentliggjorde i dag lanceringen af produktet ’miRSIGN™ miR-21 Oncogene’, et kit til forskningsbrug, der kan måle niveauet af...
Exiqon tager licens til rettighederne for validerede biomarkører indenfor prostatakræft fra Aarhus Universitetshospital
03 déc. 2014 08h36 HE
|
Exiqon A/S
København, 2014-12-03 14:36 CET (GLOBE NEWSWIRE) --
Exiqon A / S annoncerede i dag, at selskabet har taget licens til prostatakræft biomarkører, opdaget og valideret af Aarhus...
Exiqon licenses validated biomarkers for prostate cancer from Aarhus University Hospital.
03 déc. 2014 08h36 HE
|
Exiqon A/S
Copenhagen, 2014-12-03 14:36 CET (GLOBE NEWSWIRE) --
Exiqon A/S today announced that the company has exclusively licensed prostate cancer biomarkers discovered and validated by Aarhus...
Exiqon A/S offentliggør finanskalender for 2015
27 oct. 2014 11h06 HE
|
Exiqon A/S
Copenhagen, 2014-10-27 16:06 CET (GLOBE NEWSWIRE) --
Nedenstående viser forventede datoer for Exiqon A/S’ afholdelse af ordinær generalforsamling samt regnskabsrapportering i...
Exiqon A/S announces financial calendar for 2015
27 oct. 2014 11h06 HE
|
Exiqon A/S
Copenhagen, 2014-10-27 16:06 CET (GLOBE NEWSWIRE) --
Exiqon A/S (NASDAQ Copenhagen: “EXQ”) today announced the expected dates for Exiqon A/S’ annual general meeting and financial reporting in...
INTERIM REPORT FOR THE PERIOD 1 JANUARY - 30 SEPTEMBER 2014 (UNAUDITED)
27 oct. 2014 10h38 HE
|
Exiqon A/S
Copenhagen, 2014-10-27 15:38 CET (GLOBE NEWSWIRE) --
Third quarter highlights include record services sales and record quarterly revenue.
Exiqon A/S (NASDAQ Copenhagen: “EXQ”) today announced...
CORRECTION: Forbedret identifikation af højrisiko patienter med stadie II tyktarmskræft
12 sept. 2014 10h07 HE
|
Exiqon A/S
Tidligere fremsendt børsmeddelelse på engelsk. Nu også på dansk.
Exiqon A/S (NASDAQ OMX Copenhagen: “EXQ”) annoncerede i dag offentliggørelsen af data fra et populationsstudie med 554...
Redefining high risk patients with stage II colon cancer
12 sept. 2014 04h19 HE
|
Exiqon A/S
Exiqon A/S (NASDAQ OMX Copenhagen: “EXQ”) today announced the publication of data from a population based study of 554 patients with stage II colon cancer, using the company’s proprietary miRCURY...
INTERIM REPORT FOR THE PERIOD 1 JANUARY - 30 June 2014 (UNAUDITED)
14 août 2014 11h18 HE
|
Exiqon A/S
Copenhagen, 2014-08-14 17:18 CEST (GLOBE NEWSWIRE) --
Exiqon A/S (NASDAQ OMX Copenhagen: “EXQ”) today announced results for the six months of 2014:
In summary (DKK million) Q2...